These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 30549256

  • 21. Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies.
    Baldini C, Martin Romano P, Voisin AL, Danlos FX, Champiat S, Laghouati S, Kfoury M, Vincent H, Postel-Vinay S, Varga A, Vuagnat P, Ribrag V, Mezquita L, Besse B, Hollebecque A, Lambotte O, Michot JM, Soria JC, Massard C, Marabelle A.
    Eur J Cancer; 2020 Apr; 129():71-79. PubMed ID: 32143106
    [Abstract] [Full Text] [Related]

  • 22. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS, Postow M, Lao CD, Schadendorf D.
    Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
    [Abstract] [Full Text] [Related]

  • 23. Association of Immune-Related Adverse Events with Pembrolizumab Efficacy in the Treatment of Advanced Urothelial Carcinoma.
    Kobayashi K, Suzuki K, Hiraide M, Aoyama T, Yokokawa T, Shikibu S, Hashimoto K, Iikura Y, Sato H, Sugiyama E, Tajima M, Hama T.
    Oncology; 2020 Oct; 98(4):237-242. PubMed ID: 31935736
    [Abstract] [Full Text] [Related]

  • 24. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
    Yoshino K, Nakayama T, Ito A, Sato E, Kitano S.
    BMC Cancer; 2019 Oct 29; 19(1):1019. PubMed ID: 31664934
    [Abstract] [Full Text] [Related]

  • 25. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
    Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, Randon G, De Braud F, Del Vecchio M.
    J Cancer Res Clin Oncol; 2019 Feb 29; 145(2):511-521. PubMed ID: 30539281
    [Abstract] [Full Text] [Related]

  • 26. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab.
    Eun Y, Kim IY, Sun JM, Lee J, Cha HS, Koh EM, Kim H, Lee J.
    Sci Rep; 2019 Oct 01; 9(1):14039. PubMed ID: 31575933
    [Abstract] [Full Text] [Related]

  • 27. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis.
    Ksienski D, Wai ES, Croteau N, Fiorino L, Brooks E, Poonja Z, Fenton D, Geller G, Glick D, Lesperance M.
    Clin Lung Cancer; 2019 Jan 01; 20(1):e97-e106. PubMed ID: 30337270
    [Abstract] [Full Text] [Related]

  • 28. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab.
    Ishihara H, Takagi T, Kondo T, Homma C, Tachibana H, Fukuda H, Yoshida K, Iizuka J, Kobayashi H, Okumi M, Ishida H, Tanabe K.
    Urol Oncol; 2019 Jun 01; 37(6):355.e21-355.e29. PubMed ID: 30935847
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy.
    Lee YJ, Kim HT, Won CH, Chang SE, Lee MW, Choi JH, Lee WJ.
    J Korean Med Sci; 2019 Jul 08; 34(26):e186. PubMed ID: 31269545
    [Abstract] [Full Text] [Related]

  • 31. Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy.
    Shafqat H, Gourdin T, Sion A.
    Semin Oncol; 2018 Jun 08; 45(3):156-163. PubMed ID: 30348532
    [Abstract] [Full Text] [Related]

  • 32. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
    Miyahara K, Noda T, Ito Y, Hidaka H, Fujimoto S, Takedomi H, Akutagawa T, Sakata Y, Shimamura T, Tominaga N, Yamaguchi D, Fujimoto K.
    Digestion; 2020 Jun 08; 101(1):60-65. PubMed ID: 31801131
    [Abstract] [Full Text] [Related]

  • 33. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
    Weinmann SC, Pisetsky DS.
    Rheumatology (Oxford); 2019 Dec 01; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
    [Abstract] [Full Text] [Related]

  • 34. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
    Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R, Grassadonia A, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Porzio G, Cannita K, Ficorella C, Buti S.
    Clin Lung Cancer; 2019 Jul 01; 20(4):237-247.e1. PubMed ID: 30885550
    [Abstract] [Full Text] [Related]

  • 35. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
    Marano AL, Clarke JM, Morse MA, Shah A, Barrow W, Selim MA, Hall RP, Cardones AR.
    Br J Dermatol; 2019 Sep 01; 181(3):580-583. PubMed ID: 30244487
    [Abstract] [Full Text] [Related]

  • 36. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.
    Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, Dousset L, Pham-Ledard A, Prey S, Beylot-Barry M, Daste A, Gross-Goupil M, Lallier J, Ravaud A, Forcade E, Bannwarth B, Truchetet ME, Richez C, Mehsen N, Schaeverbeke T, FHU ACRONIM.
    Ann Rheum Dis; 2018 Mar 01; 77(3):393-398. PubMed ID: 29146737
    [Abstract] [Full Text] [Related]

  • 37. Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective.
    Steven NM, Fisher BA.
    Rheumatology (Oxford); 2019 Dec 01; 58(Suppl 7):vii29-vii39. PubMed ID: 31816079
    [Abstract] [Full Text] [Related]

  • 38. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
    Aggarwal P.
    Expert Opin Drug Saf; 2019 Jul 01; 18(7):623-633. PubMed ID: 31088310
    [Abstract] [Full Text] [Related]

  • 39. Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor.
    Alessandrino F, Sahu S, Nishino M, Adeni AE, Tirumani SH, Shinagare AB, Awad MM.
    Abdom Radiol (NY); 2019 May 01; 44(5):1917-1927. PubMed ID: 30790009
    [Abstract] [Full Text] [Related]

  • 40. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
    Toi Y, Sugawara S, Kawashima Y, Aiba T, Kawana S, Saito R, Tsurumi K, Suzuki K, Shimizu H, Sugisaka J, Ono H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y.
    Oncologist; 2018 Nov 01; 23(11):1358-1365. PubMed ID: 29934411
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.